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Bortezomib is a proteasome inhibitor used for hematologic cancer treatment. Since it can suppress NF-𝜅B activation, which is
critical for the inflammatory process, bortezomib has been found to possess anti-inflammatory activity. In this study, we evaluated
the effect of bortezomib on experimental autoimmune uveitis (EAU) in mice and investigated the potential mechanisms related
to NF-𝜅B inactivation. High-dose bortezomib (0.75mg/kg), low-dose bortezomib (0.15mg/kg), or phosphate buffered saline was
given after EAU induction. We found that the EAU is ameliorated by high-dose bortezomib treatment when compared with low-
dose bortezomib or PBS treatment.TheDNA-binding activity of NF-𝜅Bwas suppressed and expression of several key inflammatory
mediators including TNF-𝛼, IL-1𝛼, IL-1𝛽, IL-12, IL-17, and MCP-1 was lowered in the high-dose bortezomib-treated group. These
results suggest that proteasome inhibition is a promising treatment strategy for autoimmune uveitis.
1. Introduction
Uveitis is among the most important causes of blindness and
severe visual impairment worldwide. About 15 to 30% of
uveitis occurs in the choroid and adjacent retina and hence
is classified as posterior uveitis or uveoretinitis [1]. Posterior
uveitis tends to damage the photoreceptor cells and lead to
permanent blindness. This severe intraocular inflammatory
disease is often associated with autoimmune responses to
unique retinal proteins [2]. Current therapies for uveitis are
based largely on immunosuppressive treatment including
corticosteroids, antimetabolites, and alkylating agents. Due
to the nonspecific nature and the dose-limiting side effects of
these drugs, the results of current treatment for autoimmune-
mediated uveitis remain unsatisfactory [3]. Novel approaches
to control the inflammatory process in uveitis hence are being
keenly developed both in humans and in animal models [4].
Experimental autoimmune uveitis (EAU), in which eye
inflammation is induced by active immunization with retinal
antigens, is the most often used rodent model for the study of
autoimmune uveitis [5]. The typical histological appearance
of EAU resembles that of human posterior uveitis, with
inflammatory cells infiltrating the vitreous cavity, retina, and
choroid and causing damage to the photoreceptor cell layer
[3]. Nuclear factor-kappa B (NF-𝜅B) has a pivotal role in
inducing inflammation. Several previous studies have shown
that there is an increased NF-𝜅B activation in EAU, and
the inhibition of NF-𝜅B can ameliorate inflammation [6, 7].
Several NF-𝜅B-regulated inflammatory mediators, including
interleukin- (IL-) 1, IL-6, tumor necrosis factor- (TNF-)
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𝛼, interferon- (IFN-) 𝛾, monocyte chemoattractant protein-
(MCP-) 1, and inducible nitric oxide synthase (iNOS), were
found to increase in animalswith EAUandmay bemodulated
by treatment targeting NF-𝜅B [3].
The degradation of ubiquitinated I𝜅B by the proteasome
is important for the activation of NF-𝜅B [8, 9]. Meanwhile,
inhibition of NF-𝜅B activation has been shown to be benefi-
cial in animal models of experimental autoimmune disease,
such as myasthenia gravis, psoriasis, arthritis, and autoim-
mune encephalomyelitis [10–13]. However, little is known
about the effectiveness of proteasome inhibition in treating
autoimmune uveitis. Here, we showed the effectiveness of
bortezomib, a 26S proteasome inhibitor, in inhibiting IRBP-
induced EAU.
2. Materials and Methods
2.1. Mice. Female C57BL/6J (B6) mice (8- to 12-weeks-old)
were obtained from the Laboratory Animal Center at the
National Cheng-Kung University and used for all experi-
ments. All experiments were performed in compliance with a
protocol approved by the Institutional Animal Care and Use
Committee of the National Cheng-Kung University and with
the ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research.
2.2. Induction and Treatment of EAU. EAU was induced as
previously described with modifications [14]. Briefly, mice
were immunized with 100 𝜇L of an emulsion of phosphate
buffered saline (PBS) containing 200𝜇g of human IRBP
peptide 1–20 (hIRBP
1–20) (GPTHLFQPSLVLDMAKVLLD)
and complete Freund’s adjuvant (CFA) containing 500𝜇g
of inactivated Mycobacterium tuberculosis H37RA (Difco
Laboratories, Detroit, MI, USA). Mice received the emulsion
at two sites on the lower back, followed by an intraperi-
toneal (i.p.) injection of 1.5 𝜇g pertussis toxin (PTX) as an
additional adjuvant. Mice were treated with PBS, bortezomib
(Millennium Pharmaceuticals, Cambridge, MA) at the doses
of 0.75 or 0.15mg/kg (Velcade (H) and (L) groups, resp.), or
etanercept (Enbrel,Wyeth Pharmaceuticals, Hampshire, UK)
at the dose of 5mg/kg in 0.1mL by i.p. injection twice a week
starting on the day of EAU induction.
2.3. Clinical Scoring of EAU. Ocular fundus of the mouse
eyes was examined by slit lamp twice a week from the
7th day after induction until the end of experiments for
clinical signs of EAU. Pupils were dilated using tropicamide
and phenylephrine hydrochloride ophthalmic solutions. The
severity of inflammation was clinically graded on a scale of
1–5 as described previously [15]. Briefly, 0 = no inflammation;
1 = focal vasculitis ≤ 5 spots or soft exudates ≤ 5; 2 = linear
vasculitis or spotted exudates < 50% of the retina; 3 = linear
vasculitis or spotted exudates ≥ 50% of the retina; 4 = retinal
hemorrhage or severe exudates and vasculitis; 5 = exudative
retinal detachment or subretinal (or vitreous) hemorrhage.
A mouse was considered to have uveitis if at least one of its
eyes had a score of two or more. The severity of uveitis is
represented as the highest clinical score achieved by either eye
in a mouse.
2.4. Histopathological Evaluation. Whole eyes were collected
at the peak of the clinical response (21 days after induction
of EAU), immersed in 10% formaldehyde, and then stored
until being processed. Fixed and dehydrated tissues were
embedded in paraffin and 3 𝜇m sections were cut through the
cornea-optic nerve plane and then stained with hematoxylin
and eosin (H&E). Presence or absence of disease was eval-
uated in a blinded fashion by examining six sections cut at
different levels for each eye.The severity of inflammation was
histologically graded on a scale of 1–4 as described previously
[16]. Briefly, 0 means no change; 1 means mild cell infiltration
and focal retinal folds; 2 means moderate cell infiltration and
retinal folds; 3 means moderate to heavy cell infiltration and
extensive retinal folding with detachments; 4 means heavy
cell infiltration with diffuse retinal detachment. Therefore,
leukocytes infiltration into the vitreous cavity and retinal
folding were considered as posterior uveitis.
2.5. Preparation of Retinal Lysate for Luminex Analysis. The
eyeswere enucleated fromeuthanizedmice.The eyeballswere
cut at the equator around the ora serrata, and the posterior
pole of the eyes was separated from the anterior pole and
lens. From the posterior pole, the neurosensory retina was
extracted from retinal pigment epithelial layer. The extract
from six retinas was placed in 300 𝜇L of 0.5%NP-40 (Abcam)
on ice (oneminute) and briefly sonicated five times for 10 sec-
onds at probe intensity of 7 (MicrosonTMXL2000Ultrasonic
liquid processor, Qsonica, LLC, Newton, CT). After removal
of the insoluble material by centrifugation (200×g for 5min),
the protein concentration of the retinal extract was measured
at 280 nm on ND-1000 Spectrophotometer. Then, the retinal
lysate was used for Luminex analysis as below.
2.6. Analysis of Inflammatory Mediators in Retinas by
Luminex. Quantification of TNF-𝛼, IFN-𝛾, IL-1𝛼, IL-1𝛽, IL-
4, IL-6, IL-12, IL-17, and MCP-1 in retinal tissues was carried
out using murine multiplexing bead immunoassays (Invitro-
gen, Carlsbad, CA) according to manufacturer’s instruction.
Briefly, 25 𝜇L of retinal samples in PBS was incubated with
antibody-coupled beads. After series of washes, a biotinylated
detection antibody was added to the beads, and the reac-
tion mixture was detected by the addition of streptavidin-
phycoerythrin.The bead set was analyzed using a flow-based
Luminex 200 suspension array system (Luminex Corpora-
tion, Austin, TX, USA).
2.7. Measurement of Proteasome Activity in the Retina. The
chymotrypsin-like and trypsin-like activity of the protea-
some of the retinas in the bortezomib or PBS-treated
mice which were sacrificed 21 days after EAU induction
was determined using commercial proteasome assay kits
(Proteasome-Glo assay systems; Promega) according to the
manufacturer’s instructions. Briefly, the Suc-LLVY-Glo sub-
strate (for chymotrypsin-like activity) or Z-LRR-Glo sub-
strate (for trypsin-like activity) was added to the mixture of
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the Proteasome-Glo buffer and the luciferin detection reagent
and incubated at room temperature for 1 hour. The retinal
tissue was minced in 100 𝜇L of ice-cold PBS containing 5mM
EDTA followed by centrifugation at 12,000 g at 4∘C for 10
minutes. A 50𝜇Lof retinal samplewas added by equal volume
of reagent mixture and incubated for 90 minutes. Finally the
luminescence of retinal sample was detected by a microplate
luminometer (Promega).
2.8. Nuclear Protein Extract and Electrophoretic Mobility
Shift Assay (EMSA) of NF-𝜅B. Nuclear protein extracts were
obtained as described previously [17]. Briefly, the retinas were
minced in 0.5mL of lysis buffer (10mMHEPES, 1.5mMKCl,
10mM MgCl
2
, 1.0mM DTT, and 1.0mM PMSF). The tissue
was homogenized, followed by centrifugation at 5,000 g at
4∘C for 10 minutes. The sediment was suspended in 200 𝜇L
of extraction buffer (20mM HEPES, 25% glycerol, 1.5mM
MgCl
2
, 420mMNaCl, 0.5mMDTT, 0.2mM EDTA, 0.5mM
PMSF, and 4 𝜇M leupeptin), and the suspension was incu-
bated on ice for 30 minutes.The sample was then centrifuged
at 12,000 g at 4∘C for 30 minutes. The supernatant containing
the nuclear proteins was collected and stored at −70∘C
until use. The protein concentration was determined with a
bicinchoninic acid assay kit (Pierce Biotechnology, Rockford,
IL). The EMSA was performed with an NF-𝜅B DNA-binding
protein detection system (Pierce Biotechnology) according to
the manufacturer’s instructions. A 10 𝜇g nuclear protein was
incubated with a biotin-labeled NF-𝜅B consensus oligonu-
cleotide probe (5󸀠-AGTTGAGGGGACTTTCCCAGGC-3󸀠)
for 30 minutes in binding buffer. The specificity of the DNA
protein binding was determined by adding a 100-fold molar
excess of unlabeled NF-𝜅B oligonucleotide for competitive
binding 10 minutes before adding the biotin-labeled probe.
2.9. Statistical Analysis. Values are shown as the mean ±
SD. For statistical comparison, data were analyzed by the
Wilcoxon signed-rank test, Student’s 𝑡-test, or Chi-square test
using Prism 5.0 software. In all tests, 𝑃 values less than 0.05
were considered statistically significant.
3. Results
3.1. A High Dose of Bortezomib Significantly Decreased Uveo-
retinitis in EAUMice. EAU was induced in mice by injecting
200𝜇g of IRBP
1–20 emulsified with CFA subcutaneously and
1.5 𝜇g of pertussis toxin (PTX) intraperitoneally as described
in Section 2. At the same time, high- (0.75mg/kg) and low-
dose (0.15mg/kg) bortezomib were injected intraperitoneally
into mice and then twice a week until the end of the
experiments. A group of mice which received PBS instead
of bortezomib served as controls. In PBS-treated group, the
disease showed sign of inflammation 9–15 days later and
developed over the following 4-5 days when it reached the
peak. Mice that received IBRP
1–20 immunization plus treat-
ment with high-dose bortezomib exhibited a significant delay
in disease onset and a significantly lower peak EAU score
over time (Figure 1(a), Table 1). While both the saline-treated
and low-dose bortezomib-treated mice had higher incidence
Table 1: Effect of high-dose versus low-dose bortezomib (Velcade)
on EAUa.
Treatment Incidence Mean peak disease score
Saline 14/19 2.16 ± 0.25
Vel (L)b 10/17 2.00 ± 0.23
Vel (H)c 3/19∗ 0.58 ± 0.18#,+
aData are compiled from three experiments in which similar results were
obtained.
bLow-dose bortezomib 0.15mg/kg ip treatment.
cHigh-dose bortezomib 0.75mg/kg ip treatment.
∗
𝑃 < 0.05, via the Chi-square test, between saline and Vel (H) groups.
#
𝑃 < 0.05, via the Wilcoxon signed-rank test, between saline and Vel (H)
groups.
+
𝑃 < 0.05, via the Wilcoxon signed-rank test, between Vel (L) and Vel (H)
groups.
of disease (14 of 19 and 10 of 17, resp.), we observed that the
high-dose bortezomib-treated mice had a significantly lower
incidence of EAU (3 of 19, 𝑃 < 0.05) (Table 1). The mice
that received saline treatment had a mean clinical severity
score of 2.16 ± 0.25 while the mice that received high-dose
bortezomib treatment had a mean clinical severity score of
0.58 ± 0.18 (𝑃 < 0.05) (Table 1). The mice that received
low-dose bortezomib treatment showed a slightly lowermean
clinical severity score of 2.00±0.23, which is not significantly
different from that of the saline-treated control group. The
fact that themajority ofmice given high-dose bortezomib had
peak scores of 1 or lower (i.e., mild or no disease) indicated
a suppressive activity of bortezomib on EAU. In addition,
examination of H&E stained paraffin fixed slides revealed
that retinal sections of eyes from EAU mice that received
high-dose bortezomib had a reduced cell infiltration into
the vitreous cavity and their retinal layer structures lacked
the retinal folds observed in the saline-treated mice (Figures
1(b)–1(e)). There was no mortality or extraocular morbidity
associatedwith the bortezomib treatment in the experimental
animals. The body weight and the level of hemoglobin of
the mice did not differ significantly between the saline- and
bortezomib-treated groups at the end of experiment (data not
shown). There was also no tumor growth or infection after
bortezomib treatment in our study.
3.2. Bortezomib Treatment Suppressed EAU More than TNF-
Alpha Antagonist Treatment. Previous studies showed that
TNF-𝛼 antagonist could also suppress uveitis in human and
mice [18, 19]. We hence compared the effect of suppression of
EAU by bortezomib or TNF-𝛼 antagonist etanercept. Borte-
zomib (0.75mg/kg) or etanercept (5mg/kg) was injected into
EAU mice twice a week from the day of EAU induction.
A group of mice that received PBS (0.1mL/mouse) served
as controls. Mice that received IRBP
1–20 immunization plus
treatment with bortezomib exhibited a significant delay in
disease onset and a significantly lower peak EAU score
over time (Figure 1(f), Table 2). The mice that received
treatment with etanercept also had lower incidence and
mean peak disease score. However, the differences between
saline- and etanercept-treated groups did not reach statistical
significance (Table 2, 𝑃 = 0.06). Therefore, treatment with
4 Mediators of Inflammation



























(c) EAU with saline (d) EAU with Vel (L) (e) EAU with Vel (H)





















Figure 1: Effect of bortezomib on clinical course of EAU induced with IRBP. (a) Comparison of clinical scores of EAU mice treated with
high-dose (0.75mg/kg) bortezomib (red line, 𝑛 = 19), low-dose (0.15mg/kg) bortezomib (black line, 𝑛 = 17), or PBS (blue line, 𝑛 = 19) in
0.1mL. Data shown are the mean clinical score (ordinate) of each experiment group over time (abscissa) and the sum of three independent
experiments. Comparison of (the course of the clinical symptoms) high-dose bortezomib-treated EAU mice (blue line) with saline-treated
mice (red line) shows a significant difference and is indicated as (∗). Comparison of high-dose bortezomib-treated (blue line) with low-dose
bortezomib-treated (black line) EAU mice also shows a significant difference and is indicated as (∗). ∗𝑃 < 0.05, via the Wilcoxon signed-
rank test. (b), (c), (d), and (e): photomicrographs of H&E stained retinal tissue. Representative photomicrographs of paraffin-fixed H&E
stained slides of the retina of (b): naı̈ve C57BL/6 mice without EAU induction, (c): EAUmice that received 0.1mL PBS treatment (∗ indicates
leukocytes in vitreous cavity; ∗∗ indicates retinal folds), (d): EAU mice that received low-dose (0.15mg/kg) bortezomib treatment, and (e):
EAU mice that received high-dose (0.75mg/kg) bortezomib treatment. The experiment was repeated three times with similar results. GCL:
ganglion cell layer. INL: inner nuclear layer. ONL: outer nuclear layer. (f) Average clinical score over time of EAU in mice with high-dose
(0.75mg/kg) bortezomib (blue line, 𝑛 = 9), etanercept (5mg/kg) (black line, 𝑛 = 6), or saline (0.1mL/mouse) treatment (red line, 𝑛 = 7). Data
shown are the mean clinical score (ordinate) of each experiment group over time (abscissa) and the sum of two independent experiments.
∗
𝑃 < 0.05, via the Wilcoxon signed-rank test.
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Figure 2:The evaluation of protein expression of inflammatory mediators in retinas of EAUmice in Luminex analysis. Decreased expression
of TNF-𝛼 (a), IL-1𝛼 (b), IL-1𝛽 (c), IL-17 (f), IL-12 (h), and MCP-1 (i) relative to the expression in the saline-treated group was noted in the
high-dose bortezomib (Vel [H]) group but not in the low-dose bortezomib (Vel [L]) group except for TNF-𝛼. In addition, there was no
significant difference on the expression of IFN-𝛾 (d), IL-4 (e), and IL-6 (g) in retinas between bortezomib and saline-treated mice. Data are
expressed as the mean SD of three independent experiments (bar graph). ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001, via Student’s 𝑡-test.
bortezomib suppressed the development and severity of EAU
more effectively than the TNF-𝛼 antagonist etanercept.There
was no mortality, morbidity, tumor growth, or infection
associatedwith the bortezomib or etanercept treatment in the
EAU mice at the end of experiment.
3.3.The Influence of Bortezomib on the Levels of Inflammatory
Mediators in Retina of EAU Mice. We then measured the
cytokine levels in retinas in EAU mice with different treat-
ment. When comparing the saline-treated group with low-
dose bortezomib group, we found that TNF-𝛼 level was lower
in the low-dose bortezomib-treated group, while the levels of
other cytokines were not significantly different (Figures 2(a)–
2(i)). Meanwhile, the levels of TNF-𝛼, IL-1𝛼, IL-1𝛽, IL-12, IL-
17, and MCP-1 in retina were significantly lower in the EAU
mice treated with high-dose bortezomib when compared
with saline-treated mice (𝑃 < 0.05 in all paired comparisons)
(Figures 2(a), 2(b), 2(c), 2(f), 2(h), and 2(i)). However, there
was no significant difference noted in IFN-𝛾, IL-4, and IL-
6 between high-dose bortezomib-treated and saline-treated
EAU mice (Figures 2(d), 2(e), and 2(g)). When comparing
the groups treated with high-dose and low-dose bortezomib,
we found that the levels of TNF-𝛼, IL-1𝛼, IL-1𝛽, IL-12, IL-17,
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Figure 3: Evaluation of chymotrypsin-like and trypsin-like activity of the proteasome. Compared to the saline-treated EAU group, there was
significantly decreased activity of chymotrypsin-like (a) and trypsin-like activity (b) in the low-dose [Vel (L)] and high-dose bortezomib [Vel
(H)] groups. The activity was also markedly lowered in the high-dose bortezomib-treated group compared with the low-dose bortezomib-
treated group. The data are expressed as the mean ± SD of the mean in 5 mice for each group (bar graph). ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and
∗∗∗
𝑃 < 0.001, via Student’s 𝑡-test. The experiment was repeated three times with similar results.
Table 2: Effect of etanercept versus bortezomib (Velcade) on EAU.
Treatment Incidence Mean peak disease score
Saline 8/9 3.33 ± 0.33
Etanercepta 3/6 2.00 ± 0.63
Velcadeb 0/7∗ 0.57 ± 0.20#
aEtanercept 5mg/kg ip treatment.
bBortezomib (Velcade) 0.75mg/kg ip treatment.
∗
𝑃 < 0.05, via the Chi-square test, between saline and bortezomib group.
#
𝑃 < 0.05, via theWilcoxon signed-rank test, between saline and bortezomib
group.
andMCP-1 were lower in the high-dose bortezomib group in
comparison with the low-dose bortezomib group (𝑃 < 0.05
in all paired comparisons) (Figures 2(a), 2(b), 2(c), 2(f), 2(h),
and 2(i)).
3.4. Bortezomib Treatment Significantly Reduced the Protea-
some Activity of EAU Mice. We then performed proteasome
protease activity assays to evaluate the suppressive effect of
bortezomib treatment in retinal tissue.The signal of lumines-
cence indicates chymotrypsin-like or trypsin-like activity in
the retinal tissues of EAUmice.The signals were significantly
lower in the high-dose bortezomib-treated group when
compared with the saline or low-dose bortezomib-treated
group (𝑃 < 0.05) (Figures 3(a) and 3(b)). There was also a
significant difference in the signal of luminescence between
the low-dose bortezomib and saline-treated groups (Figures
3(a) and 3(b)).
3.5. The Increased Binding of NF-𝜅B and DNA in EAU Mice
Was Inhibited by Bortezomib Treatment. The involvement of
NF-𝜅B pathway during bortezomib treatment in EAU was
analyzed with EMSA. Compared to the näıve group, the NF-
𝜅B DNA binding increased after EAU induction significantly
(Figure 4, Shift of Näıve and Saline). The increased activity
of NF-𝜅B DNA binding after EAU induction was markedly
inhibited by treatment with low-dose bortezomib. High-dose
bortezomib treatment further suppressed the NF-𝜅B DNA
binding (Figure 4, Shift of Vel (L) and Vel (H)). Adding a
100-fold molar excess of unlabeled NF-𝜅B probe completely
blocked the binding of the labeled probe to the NF-𝜅B DNA
complex (Figure 4, Shift of 100X). Therefore, bortezomib
reduced the binding of NF-𝜅B DNA in a dose-responsive
manner. The results from protease inhibition (Figure 3) and
NF-𝜅B DNA binding implicated that the activation of NF-𝜅B
was effectively suppressed by proteasome inhibition.
4. Discussion
Our study demonstrated that bortezomib, a 26S proteasome
inhibitor, is active in suppressing NF-𝜅B activation and is
effective in inhibiting ocular inflammation and reducing the
production of inflammatory mediators in EAU. Our results
indicate that inhibition of proteasome may be a promising
approach to treating autoimmune uveitis.
Recent evidence indicated thatNF-𝜅Bhas a pivotal role in
EAU and that the inhibition of NF-𝜅B activation can reduce
the levels of tissue inflammation by lowering the inflam-
matory mediators and cell infiltration into the uvea [6, 7].





























Figure 4: EMSA for the evaluation of the NF-𝜅B DNA-binding
activity in näıve mice and different groups of EAUmice. Lane 1: p50
subunit of NF-𝜅B. Lane 2: free probe (FP). Lane 3: näıve C57BL/6
mice. Lane 4: EAU mice with saline treatment. Lane 5: EAU mice
treated with low-dose bortezomib (Vel [L]). Lane 6: EAU mice
treated with high-dose bortezomib (Vel [H]). Lane 7: 100-foldmolar
excess of unlabeledNF-𝜅Bprobe. Lane 8: anti-p65 subunit ofNF-𝜅B.
The sample was pooled from both eyes of five mice in each group.
Data are representative of results in three independent experiments.
Since proteasomal degradation of the inhibitory factor I𝜅B is
important for NF-𝜅B activation, the inhibition of proteasome
maintains NF-𝜅B in the inactive state in the cytosol and
prevents its nuclear translocation. Proteasome inhibition
has been found to be effective in treating several animal
models of autoimmune disease such as myasthenia gravis,
psoriasis, arthritis, and autoimmune encephalomyelitis [10–
13]. Moreover, Chen et al. have shown the anti-inflammatory
effect of proteasome inhibitor on endotoxin-induced uveitis
in rats [17]. The proteasome inhibitors bortezomib, due to
their activity to suppress nonlysosomal protein degradation,
has been used in the treatment of hematologic cancers in
clinical settings [20]. In this study, we chose bortezomib
based on its high efficacy at minimal concentrations and
tolerable and manageable adverse effects in treating human
hematologic diseases [21]. To our knowledge, our study is the
first to demonstrate its anti-inflammatory effect in EAU.
Being an autoantigen-induced autoimmune condition,
EAU has an inflammation dominated by acute inflammatory
cytokine response [3]. In our study, we found that levels
of inflammatory mediators including TNF-𝛼, IL-1𝛼, IL-1𝛽,
IL-12, IL-17, and MCP-1 increased significantly in saline-
treated EAU mice when compared with those in näıve mice
(Figure 2). TNF-𝛼 is a major proinflammatory cytokine and
plays a central role in autoimmune uveitis [3]. TNF-𝛼 antag-
onists have been used clinically to treat ocular inflammatory
disorders successfully [19, 22]. Therefore, in this study we
compared the anti-inflammatory effect between proteasome
inhibitor bortezomib and the TNF-𝛼 antagonist, etanercept,
in EAU. Etanercept, a chimeric protein of human TNF-𝛼
receptor and Fc portion of immunoglobulin G heavy chain,
can neutralize TNF-𝛼 and inhibit its proinflammatory activ-
ity in both humans andmice [18, 23, 24].We found that borte-
zomib treatment in EAU mice could suppress not only TNF-
𝛼 but also many other inflammatory mediators such as IL-1𝛼,
IL-1𝛽, IL-12, IL-17, and MCP-1 in retinas so the autoimmune
uveitis could be more effectively suppressed with bortezomib
than with TNF-𝛼 antagonist etanercept (Figure 1(f)). Borte-
zomib, which may suppress multiple inflammatory cytokines
through inhibiting NF-𝜅B activation, hence appears to be a
better anti-inflammatory agent in treatment of autoimmune
uveitis than TNF-𝛼 antagonists.
The mechanisms of the anti-inflammatory effects of
bortezomib, however, may be more complex than the inhi-
bition of NF-𝜅B activation. As the induction of EAU appar-
ently involves the antigen presentation of the immunogenic
antigen by major histocompatibility complex class I and class
II molecules, the inhibition of proteasome, which is a critical
component of the antigen processing, may also affect the
autoimmune recognition process in sensitization and stim-
ulation phases [25–29]. In addition, proteasome inhibitors
have been demonstrated to trigger the apoptosis of leukocytic
cells, which may contribute to their immunosuppressive
and antitumor effect [30–33]. Proteasome inhibition hence
may suppress several key steps necessary for activating the
autoimmune responses in EAU.
In our study, the mice were treated with bortezomib
from the same day when EAU was induced to ensure the
onset of the drug’s effect during early stage of the disease
development. We have not evaluated the drug’s efficacy
when it is applied after EAU is full-blown, as usually is
the case in clinic settings. At the end of experiment after
bortezomib or etanercept treatment, there was no mortality,
tumor growth, or severe infection noted. However, since the
proteasome and its ubiquitous distribution regulate the wide
range of biological functions, the systemic adverse effects
associated with proteasome inhibitors deserve meticulous
consideration.
In summary, we demonstrated that bortezomib amelio-
rated experimental autoimmune uveitis in mice in a dose-
dependent manner. Reduced intraocular inflammation was
associated with the inhibition of NF-𝜅B activation and
decreased expression of many inflammatory mediators. Our
encouraging results indicate that drugs targeting the protea-
some may be an effective treatment strategy for autoimmune
uveitis in the future.
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